Welcome to our dedicated page for Microbot Med SEC filings (Ticker: MBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Microbot Medical filings document formal disclosures tied to the LIBERTY Endovascular Robotic System and the company’s commercial-stage medical-device operations. Recent Form 8-K reports furnish Regulation FD press releases on U.S. market release activity, healthcare-system adoption, procedure use, medical-society occupational-protection guidelines, and publication of the ACCESS-PVI pivotal study.
The filings also record Item 8.01 other-event disclosures and capital-markets matters, including an at-the-market common stock program under a shelf registration statement. These records describe the company’s Nasdaq-listed common stock, product commercialization, clinical-evidence communications, commercial organization updates, and related exhibit filings.
Microbot Medical Inc. reported that a pivotal clinical study of its LIBERTY® Endovascular Robotic System has been published in the peer‑reviewed Journal of Vascular and Interventional Radiology. The article analyzes the ACCESS-PVI multicenter feasibility study, whose lead principal investigator was Dr. Francois Cornelis.
The company notes that publication follows completion of the ACCESS-PVI study in 2025 and its presentation at the Society of Interventional Radiology meeting. LIBERTY received U.S. FDA clearance in September 2025 for peripheral endovascular procedures. Microbot began a limited market release in late 2025 and plans a full market release at the Society of Interventional Radiology conference in April 2026.
Microbot Medical Inc. furnished an 8-K to share that it will participate in the Roth Annual Growth Conference in Laguna Niguel, California from March 22-24, 2026. CEO Harel Gadot will join a live fireside Q&A on March 23, with a webcast available through the company’s website.
The company also released updated investor presentation materials, accessible online, highlighting progress with its LIBERTY Endovascular Robotic System. LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, moving from a limited market release that began in late 2025 toward a planned full market release at the SIR conference in April 2026.
Microbot Medical Inc. filed a report to share that it will participate in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, held March 16–19, 2026. CEO, President and Chairman Harel Gadot will present live at 8:40 a.m. ET on March 19, 2026.
The company will highlight the expanding clinical experience and recent achievements from the limited market release of its LIBERTY Endovascular Robotic System. LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Microbot began a limited market release in late 2025 and plans a full market release at the Society of Interventional Radiology conference in April 2026.
Microbot Medical Inc. filed a current report describing a press release about its LIBERTY® Endovascular Robotic System and recent policy from the American Medical Association on occupational radiation exposure. The AMA adopted a policy in late 2025 to strengthen protections for health care professionals and trainees exposed to ionizing radiation.
Microbot emphasizes that LIBERTY is remotely operated and, in the ACCESS-PVI Study, use of the system showed a 92% relative reduction in radiation exposure. The company began a Limited Market Release of LIBERTY in late 2025 and plans a Full Market Release at the Society of Interventional Radiology conference in April 2026.
Microbot Medical Inc. reported that its operations and commercial activities remain stable despite current geopolitical events in the Middle East. The company states there is no business disruption in either the U.S. or Israel, and that employee safety and security remain a top priority.
Following recent FDA clearance of its LIBERTY Endovascular Robotic System, Microbot is focusing commercialization on the U.S. market using a dedicated commercial team based in Hingham, Massachusetts. The company indicates internal operations and its lead manufacturing partner are fully functional, with sufficient U.S. inventory and additional stock being built through a third-party logistics partner.
Microbot is preparing for a full market release of the LIBERTY System at the Society of Interventional Radiology conference in April 2026, after beginning a limited market release in late 2025. To support expansion, it has hired additional U.S. sales representatives and a Director of Health Economics and Outcomes Research, while continuing to monitor Middle East developments to maintain uninterrupted customer support.
Microbot Medical Inc. reported changes to its executive employment arrangements and a one-time cash award. As of February 20, 2026, the company entered into an addendum to the employment agreement with Simon Sharon, an addendum with Rachel Vaknin, and an amendment to the employment agreement with Juan Diaz-Cartelle. On February 18, 2026, the board also authorized a special bonus of approximately $140,000 for CEO, President and Chairman Harel Gadot, which is in addition to bonuses he may receive under his existing employment agreement.
Microbot Medical reported that Tampa General Hospital has become the first health system in Florida to adopt its LIBERTY® Endovascular Robotic System, following recent FDA 510(k) clearance. The company sees this as early post-clearance momentum in a U.S. peripheral endovascular market of about 2.5 million procedures annually.
Microbot began a limited market release of LIBERTY in late 2025 and plans a full commercial launch at the Society of Interventional Radiology conference in April 2026. LIBERTY is described as a single-use, remotely operated robotic system designed to improve precision and reduce radiation exposure and physical strain during peripheral endovascular procedures.
Gadot Harel reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that Chairman, President and CEO Harel Gadot received a grant of stock options covering 480,000 shares of common stock. These options were awarded under the company’s 2020 Omnibus Performance Award Plan.
According to the grant terms, 25% of the option vests and becomes exercisable on August 18, 2026. The remaining 75% vests and becomes exercisable in equal installments on a quarterly basis over the following 30 months, subject to the plan’s provisions on possible acceleration or forfeiture.
Diaz-Cartelle Juan reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that Chief Medical Officer Juan Diaz-Cartelle received a grant of stock options covering 105,000 shares of common stock. These options were awarded at no cost as part of his compensation.
Under the company’s 2020 Omnibus Performance Award Plan, 25% of the options will vest and become exercisable on August 18, 2026. The remaining 75% will vest in equal installments on a quarterly basis over the following 30 months, subject to possible acceleration or forfeiture under the plan terms.
Sharon Simon reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that General Manager and CTO Sharon Simon was granted stock options covering 105,000 shares of common stock. According to the company’s 2020 Omnibus Performance Award Plan, 25% of the options vest and become exercisable on August 18, 2026, with the remaining 75% vesting in equal quarterly installments over the following 30 months, subject to the plan’s acceleration or forfeiture provisions.